author-photo

M. Phillip DeYoung

GlaxoSmithKline

12

Papers

229

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer

2019 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (6)
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

2019 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (8)
Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma

2019 Blood
Show All
- Source
- Cite
- Save
Citations (3)
A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors

2017 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (69)
Abstract IA22: Targeting inducible T cell co-stimulator (ICOS) promotes effector T cell function and antitumor response

2016 Cancer immunology research
Show All
- Source
- Cite
- Save
Citations (0)
Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230

2016 Oncotarget
Show All
- Source
- Cite
- Save
Citations (25)
Abstract 5449: FP-1039/GSK3052230, an FGF ligand trap, enhances VEGF antagonist therapy in preclinical models of RCC and HCC

2014 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1

2011 Biochemical Journal
Show All
- Source
- Cite
- Save
Citations (113)
Abstract LB-116: GSK2334470: A potent and highly selective inhibitor of PDK1

2010 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)